Back to Single Peptide Protocols
Single PeptideMetabolic & Weight Loss5 mg vialWeeklySubcutaneousGLP-1
Semaglutide (5 mg Vial) Dosage Protocol
Detailed semaglutide dosage protocol with titration schedule and weekly injection guidance for the 5 mg research vial.
Vial Size
5 mg
Route
Subcutaneous
Frequency
Once weekly
Dose Range
0.25–2.4 mg/week
Dosage Schedule
| Period | Dose |
|---|---|
| Weeks 1–4 | 0.25 mg |
| Weeks 5–8 | 0.5 mg |
| Weeks 9–12 | 1.0 mg |
| Weeks 13+ | 1.7–2.4 mg |
Route: Subcutaneous · Frequency: Once weekly · Cycle: 12–52 weeks
How It Works
Semaglutide is a GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves insulin sensitivity. It is the active ingredient in Ozempic (diabetes) and Wegovy (obesity).
Potential Benefits
- •Clinically proven weight loss of 15–20% body weight in STEP trials.
- •Improves glycemic control in type 2 diabetes.
- •Cardiovascular risk reduction demonstrated in SELECT trial.
- •Once-weekly dosing improves adherence.
Side Effects & Risks
- •Nausea, vomiting, diarrhea (most common, usually transient).
- •Risk of pancreatitis (rare).
- •Contraindicated with personal/family history of MTC or MEN2.
Important Notes
- Titrate slowly to minimize GI side effects.
- Inject in abdomen, thigh, or upper arm; rotate sites weekly.
- FDA-approved for diabetes (Ozempic) and obesity (Wegovy).
Storage Instructions
- Lyophilized: −20 °C (−4 °F).
- Once mixed: 2–8 °C; use within 28 days.
References
- [1]Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021.View Source
- [2]Ozempic (semaglutide) Prescribing Information. Novo Nordisk 2023.View Source
Research & Educational Use Only: This protocol is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any decisions related to peptides or any other compounds.